Global prevalence of congenital color vision deficiency among children and adolescents, 1932-2022
- PMID: 40769301
- DOI: 10.1016/j.ophtha.2025.07.031
Global prevalence of congenital color vision deficiency among children and adolescents, 1932-2022
Abstract
Purpose: To estimate the prevalence of congenital color vision deficiency (CVD), categorized by geographical region, ethnicity, type (deutan, protan, and tritan), and severity (anomalous trichromacy, dichromacy, and monochromacy).
Design: Systematic review and meta-analysis of the literature.
Participants: A total of 1,703,619 participants, including 31,493 patients from 56 studies across 21 countries and five continents, were included in our analysis.
Methods: We conducted a systematic search of PubMed/MEDLINE, Embase, CINAHL, and Google Scholar databases from 1930 to August 12, 2024. We used strict inclusion criteria, limiting the analysis to studies on children and adolescents in the general population. National and regional prevalence estimates were analyzed, with additional sub-analyses by ethnicity, type, and severity. A random-effects model was utilized to calculate pooled prevalence estimates with 95% confidence intervals (CIs), and heterogeneity was assessed using the I2 statistic.
Main outcome measures: Pooled estimates for the prevalence of CVD.
Results: The global prevalence of CVD was estimated at 2.59% (95% CI, 2.20-3.03, I2 =99.37), with higher rates observed in males (4.38% [3.93-4.88]) compared to females (0.64% [0.46-0.89]). Among ancestries, individuals of European descent exhibited the highest prevalence (2.77% [2.10-3.64]), closely followed by those of African descent (2.69% [2.21-3.28]). Regionally, Oceania displayed the highest prevalence (4.37% [3.36-5.68]), followed by Africa (2.86% [2.36-3.46]). Across all CVD types and severities, males consistently showed higher prevalence rates than females. In terms of CVD types, the highest prevalence was observed for deutan in both sexes (males: 3.66% [3.02-4.44]; females: 0.46% [0.30-0.69]), followed by protan (males: 1.54% [1.30-1.82]; females: 0.30% [0.21-0.43]) and tritan (males: 0.67% [0.20-2.22]). Regarding severity, males had the highest prevalence of dichromacy (1.59% [1.33-1.90]), followed by anomalous trichromacy (1.17% [0.89-1.55]) and monochromacy (0.36% [0.22-0.61]). For females, anomalous trichromacy had the highest prevalence (0.38% [0.25-0.56]), followed by dichromacy (0.27% [0.19-0.39]) and monochromacy (0.10% [0.04-0.21]).
Conclusions: This study highlights that the prevalence of CVD varies significantly by region and ethnicity.
Keywords: Adolescents; color vision deficiency; deutan defect; protan defect; tritan defect.
Copyright © 2025. Published by Elsevier Inc.
Similar articles
-
Smoking cessation for secondary prevention of cardiovascular disease.Cochrane Database Syst Rev. 2022 Aug 8;8(8):CD014936. doi: 10.1002/14651858.CD014936.pub2. Cochrane Database Syst Rev. 2022. PMID: 35938889 Free PMC article.
-
Falls prevention interventions for community-dwelling older adults: systematic review and meta-analysis of benefits, harms, and patient values and preferences.Syst Rev. 2024 Nov 26;13(1):289. doi: 10.1186/s13643-024-02681-3. Syst Rev. 2024. PMID: 39593159 Free PMC article.
-
Healthcare outcomes assessed with observational study designs compared with those assessed in randomized trials.Cochrane Database Syst Rev. 2014 Apr 29;2014(4):MR000034. doi: 10.1002/14651858.MR000034.pub2. Cochrane Database Syst Rev. 2014. Update in: Cochrane Database Syst Rev. 2024 Jan 4;1:MR000034. doi: 10.1002/14651858.MR000034.pub3. PMID: 24782322 Free PMC article. Updated.
-
Surveillance for Violent Deaths - National Violent Death Reporting System, 50 States, the District of Columbia, and Puerto Rico, 2022.MMWR Surveill Summ. 2025 Jun 12;74(5):1-42. doi: 10.15585/mmwr.ss7405a1. MMWR Surveill Summ. 2025. PMID: 40493548 Free PMC article.
-
Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.Cochrane Database Syst Rev. 2022 Sep 26;9(9):CD015048. doi: 10.1002/14651858.CD015048.pub2. Cochrane Database Syst Rev. 2022. PMID: 36161421 Free PMC article.
LinkOut - more resources
Full Text Sources